Download PDF
Thromb Haemost 1998; 79(02): 276-281
DOI: 10.1055/s-0037-1614977
Letters to the Editor
Schattauer GmbH

The Role of the Tissue Factor Pathway in the Hypercoagulable State in Patients with the Antiphospholipid Syndrome

Olga Amengual
1   From the Lupus Research Unit, The Rayne Institute, St. Thomas’ Hospital, London, United Kingdom
,
Tatsuya Atsumi
1   From the Lupus Research Unit, The Rayne Institute, St. Thomas’ Hospital, London, United Kingdom
,
Munther A. Khamashta
1   From the Lupus Research Unit, The Rayne Institute, St. Thomas’ Hospital, London, United Kingdom
,
Graham R. V. Hughes
1   From the Lupus Research Unit, The Rayne Institute, St. Thomas’ Hospital, London, United Kingdom
› Author Affiliations
Further Information

Publication History

Received 13 May 1997

Accepted after resubmission 19 September 1997

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

The antiphospholipid syndrome (APS) is characterised by both arterial and venous thrombosis, recurrent pregnancy loss and thrombocytopaenia in association with antiphospholipid antibodies (aPL). To explore further the pathogenesis of thrombosis in APS, we evaluated the behaviour of tissue factor (TF) pathway in patients with APS. Plasma antigen levels of soluble TF and tissue factor pathway inhibitor (TFPI), a physiological regulator of TF dependent coagulation activation, were measured in 57 APS patients (36 primary and 21 secondary to systemic lupus erythematosus). Significantly elevated levels of both TF and TFPI were found in APS patients compared with 25 healthy controls (279 ± 15 vs. 217 ± 17 pg/ml, p = 0.01; 56.24 ± 2.00 vs. 47.92 ± 2.22 ng/ml, p = 0.01, respectively), suggesting in vivo upregulation of TF pathway in patients with APS. By flow-cytometry, monocytes from a healthy donor displayed higher TF antigen expression when incubated in the presence of APS plasmas than in control plasmas (24.23 ± 3.11 vs. 12.78 ± 1.57%, p = 0.002). Peripheral blood mononuclear cells (PBMC) also expressed more procoagulant activity (PCA) when incubated in the presence of APS plasmas than in control plasmas (1.80 ± 0.12 vs. 1.35 ± 0.054, p = 0.001) implying that TF up-regulation in APS was reproducible in vitro. Human monoclonal anticardiolipin antibodies induced PCA on PBMC and also TF mRNA on both PBMC and human umbilical vein endothelial cells shown by reverse-transcription polymerase chain reaction. These data strongly suggest that the TF pathway is implicated in the pathogenesis of aPL related thrombosis.

 

  • References

  • 1 Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-4.
    CrossrefPubMedGoogle Scholar
  • 2 Carreras LO, DeFreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death, and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; i: 244-6.
    PubMedGoogle Scholar
  • 3 Violi F, Ferro D, Valesini G, Quintarelli C, Saliola M, Grandilli MA, Balsano F. Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. Brit Med J 1990; 300: 1099-102.
    CrossrefPubMedGoogle Scholar
  • 4 Ames PRJ, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idopathic antiphospholipid antibodies – a crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76: 190-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-7.
    CrossrefPubMedGoogle Scholar
  • 6 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-25.
    PubMedGoogle Scholar
  • 7 Arvieux J, Roussel B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to 2-glycoprotein I. Thromb Haemost 1993; 70: 336-41.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by 2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 1328-32.
    PubMedGoogle Scholar
  • 10 Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-10.
    CrossrefPubMedGoogle Scholar
  • 11 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
    PubMedGoogle Scholar
  • 12 Petersen LC, Valentin S, Hedner U. Regulation of the extrinsic pathway system in health and disease: The role of factor VIIa and Tissue Factor pathway inhibitor. Thromb Research 1995; 79: 1-47.
    CrossrefPubMedGoogle Scholar
  • 13 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 9: 2752-5.
    CrossrefPubMedGoogle Scholar
  • 14 Mackman N. Regulation of the Tissue Factor Gene. FASEB J 1995; 9: 883-9.
    CrossrefPubMedGoogle Scholar
  • 15 Courtney MA, Haidaris PJ, Marder VJ, Sporn LA. Tissue factor mRNA expression in the endothelium of an intact umbilical vein. Blood 1996; 87: 174-9.
    PubMedGoogle Scholar
  • 16 Colucci M, Balconi G, Lorenzet R, Locati D, Donati MB, Semerano N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-6.
    CrossrefPubMedGoogle Scholar
  • 17 Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53: 231-41.
    CrossrefPubMedGoogle Scholar
  • 18 Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone Jr. MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-7.
    CrossrefPubMedGoogle Scholar
  • 19 Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-4.
    CrossrefPubMedGoogle Scholar
  • 20 Herbert JM, Savi P, Laplaca MC, Lale A. IL-4 inhibits LPS, IL-1beta and TNF alpha induced expression of tissue factor in endothelial cells and monocytes. FEBS Lett 1992; 310: 31-3.
    CrossrefPubMedGoogle Scholar
  • 21 Lin MC, Almus-Jacobs F, Chen HH, Parry GCN, Mackman N, Shyy JYJ, Chien S. Shear stress induction of the tissue factor gene. J Clin Invest 1997; 99: 737-44.
    CrossrefPubMedGoogle Scholar
  • 22 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Broze GJJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-43.
    PubMedGoogle Scholar
  • 24 Rapaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Broze GJJ. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-3.
    PubMedGoogle Scholar
  • 26 Kazama Y. The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmatic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor. Thromb Haemost 1997; 77: 492-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-12.
    CrossrefPubMedGoogle Scholar
  • 28 Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991; 78: 1496-502.
    PubMedGoogle Scholar
  • 29 Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze JGJ, Warren TG, Wun TC. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 76: 1538-45.
    PubMedGoogle Scholar
  • 30 Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coag Fibrin 1993; 4: 699-706.
    CrossrefPubMedGoogle Scholar
  • 31 Holst J, Lindblad B, Bergqvist D, Nordfang O, Ostergaard PB, Peterson JG, Nielsen G, Hedner U. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis – a comparison with low molecular weight heparin. Thromb Haemost 1994; 71: 214-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9.
    PubMedGoogle Scholar
  • 33 Ichikawa K, Khamashta M, Koike T, Matsuura E, Hughes GRV. Reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome to 2-glycoprotein I. Arthritis Rheum 1994; 37: 1453-61.
    CrossrefPubMedGoogle Scholar
  • 34 Verhagen HJM, Heijnen-Snyder GJ, Vink T, Pronk A, van Vroonhoven TJMV, Eikelboom BC, Sixma JJ, de Groot PG. Tissue factor expression on mesothelial cells is induced during in vitro culture-manipulation of culture conditions creates perspectives for mesothelial cells as a source for cell seeding procedures vascular grafts. Thromb Haemost 1995; 74: 1096-102.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Harris EN, Gharavi AE, Patel BM, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-22.
    PubMedGoogle Scholar
  • 36 Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GRV. Specificity of ELISA for antibody to 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996; 35: 1239-43.
    CrossrefPubMedGoogle Scholar
  • 37 Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Cáliz R, Hughes GRV. Prevalence and clinical significance of antiprothrombin antibodies (aPT) in antiphospholipid syndrome. Br J Rheumatol 1997; 36: 17.
    PubMedGoogle Scholar
  • 38 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” antibodies. Blood 1994; 84: 2854-67.
    PubMedGoogle Scholar
  • 39 Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of Factor XII in plasma by 2-glycoprotein I and anti- 2-glycoprotein I. Thromb Haemost 1995; 73: 798-804.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. 2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996; 75: 49-55.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by anti-phospholipid antibodies. J Clin Invest 1995; 96: 2211-9.
    CrossrefPubMedGoogle Scholar
  • 42 Del PaPa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GRV, Meroni PL. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum 1997; 40: 551-61.
    CrossrefPubMedGoogle Scholar
  • 43 Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 536-41.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997; 77: 222-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Albrecht S, Kotzsch M, Siegert G, Luther T, Großmann H, Großer M, Müller M. Detection of circulating tissue factor and factor VII in a normal population. Thromb Haemost 1996; 75: 772-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Wada H, Nakase T, Nakaya R, Minamikawa K, Wakita Y, Kaneko T, Ohiwa M, Deguchi K, Shirakawa S. Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation. Am J Hematol 1994; 45: 232-6.
    CrossrefPubMedGoogle Scholar
  • 47 Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: Comparison of its behavior with plasma tissue factor. Thromb Res 1995; 80: 339-48.
    CrossrefPubMedGoogle Scholar
  • 48 Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Matsuzawa K, Hasegawa R, Aoki N. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 87: 343-7.
    CrossrefPubMedGoogle Scholar
  • 49 Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995; 73: 10-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Cuadrado MJ, López-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, Hughes GRV, Velasco F. Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 834-41.
    CrossrefPubMedGoogle Scholar
  • 51 Abumiya T, Yamaguchi T, Terasaki T, Kokawa T, Kario K, Kato H. Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 1995; 74: 1050-4.
    Article in Thieme ConnectPubMedGoogle Scholar